| In silico drug screen reveals potential competitive MTHFR inhibitors for clinical repurposing N Keske, B Özay, EY Tükel, M Menteş, C Yandım Journal of Biomolecular Structure and Dynamics 41 (21), 11818-11831, 2023 | 2 | 2023 |
| In Silico Drug Repurposing Against PSMB8 as a Potential Target for Acute Myeloid Leukemia Treatment EY Tükel, O Ateş, Y Kiraz Molecular Biotechnology, 1-11, 2024 | 1 | 2024 |
| Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities B Budak, EY Tükel, B Turanlı, Y Kiraz Annals of Hematology, 1-14, 2024 | 1 | 2024 |
| Identification of potential inhibitors for drug resistance in acute lymphoblastic leukemia through differentially expressed gene analysis and in silico screening B Özay, EY Tükel, GA Duran, Y Kiraz Analytical Biochemistry 694, 115619, 2024 | | 2024 |
| Correction to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities B Budak, EY Tükel, B Turanlı, Y Kiraz Annals of Hematology 103 (9), 3835, 2024 | | 2024 |
| Increasing treatment efficacy by drug repositioning in acute lymphoblastic leukemia EY Tükel İzmir Ekonomi Üniversitesi, 2024 | | 2024 |
| P345: IN SILICO DRUG REPURPOSING STUDY AND MOLECULAR SIGNATURE IDENTIFICATION ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA YK Durmaz, B Budak, EY Tükel, B Turanli HemaSphere 7 (S3), e4637231, 2023 | | 2023 |
